Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Mar 18, 2024 08:00 ET
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive...
Mar 18, 2024 08:00 ET
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a...
Mar 18, 2024 08:00 ET
Aruna Bio to Participate in Upcoming Investor Conferences
Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at upcoming investor...
Mar 18, 2024 08:00 ET
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team...
Mar 18, 2024 08:00 ET
Auddia Announces New $3.5M Financing
via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), developer of a proprietary AI platform for audio and innovative technologies for podcasts that is reinventing how consumers engage with audio, today announced...
Mar 18, 2024 08:00 ET
Auto Parts 4 Less Group Inc. Continues to Strengthen Balance Sheet with Additional Debt Conversion
Auto Parts 4 Less Group Inc. (OTC: FLES) ("AutoParts4Less," "the Company"), a technology-driven e-commerce leader in the automotive parts sector, is pleased to announce another significant step in its ongoing efforts to improve its financial...
Mar 18, 2024 08:00 ET
Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination
Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from March 14, 2024 for an additional...
Mar 18, 2024 08:00 ET
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The...
Mar 18, 2024 08:00 ET
ContextLogic Files Definitive Proxy Statement Regarding Proposed Transaction with Qoo10
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) today announced that a special meeting of its stockholders has been called to consider and vote on its proposed transaction with Qoo10 Pte. Ltd. (“Qoo10”), among other...
Mar 18, 2024 08:00 ET
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which...
Mar 18, 2024 08:00 ET
Duos Technologies Group Sets Fourth Quarter and Full Year 2023 Earnings Call for Monday, April 1, 2024 at 4:30 PM ET
Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT) through its operating subsidiary Duos Technologies, Inc. a provider of Machine Vision and Artificial Intelligence (“AI”) to analyze fast moving freight, passenger and transit...
Mar 18, 2024 08:00 ET
DZS Further Transforms Economics of Optical Edge with Launch of Saber 2200 Coherent xHaul Ethernet Switch
DZS (Nasdaq: DZSI), a global leader of access, optical and AI-driven cloud software solutions, today introduced its next expansion of the category-defining Saber portfolio – the DZS Saber 2200 transport switch. This hardened, high capacity, low...
Mar 18, 2024 08:00 ET
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription...
Mar 18, 2024 08:00 ET
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the...
Mar 18, 2024 08:00 ET
Gabelli Funds to Host 10th Annual Waste & Sustainability Symposium Thursday, April 4, 2024
Gabelli Funds, LLC, will host the 10th Annual Waste & Sustainability Symposium at the Harvard Club in New York City on Thursday, April 4, 2024. The symposium will draw companies with a focus on the themes of waste, water treatment, and the...
Mar 18, 2024 08:00 ET
HireVue Joins US Artificial Intelligence Safety Institute Consortium
HireVue, the pioneer and global leader in Human Potential Intelligence, today announced that the company has joined the U.S. Artificial Intelligence Safety Institute Consortium, established by the National Institute of Standards and Technology...
Mar 18, 2024 08:00 ET
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31,...
Mar 18, 2024 08:00 ET
IEEE-ISTO Announces Formation of the Waveform Architecture for Virtualized Ecosystems (WAVE) Consortium
IEEE-ISTO, an international federation of leading groups and consortia dedicated to the advancement of standardized technologies for the benefit of industry, today announces its newest member program, the WAVE Consortium. Waveform Architecture...
Mar 18, 2024 08:00 ET
Improving literacy rates critical to quality of life: United for Literacy survey
The majority of Canadians (92 per cent) believe improving literacy rates in Canada would improve Canadians’ standard of living, according to a new Pollara survey commissioned by United for Literacy (formerly Frontier College). The national survey...
Mar 18, 2024 08:00 ET
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that its CEO, Jeffrey Meckler, will present and participate in an open Q&A on...